Therapeutics News and Research

RSS

More synergy in public health between Methodist-Houston and Weill Cornell

A noted authority in health services research, critical care and geriatric medicine, Dr. Marc D. Silverstein has been appointed chairman of a newly created Department of Public Health at The Methodist Hospital in Houston.

11 Mar 2007

Archemix granted two European patents

Archemix has announced today the issuance of two key, broad patents by the European Patent Office ("EPO"). The patents, EP 0 786 469 and EP 0 668 931, broadly cover methods for the identification and use of aptamers for therapeutic applications.

8 Mar 2007

Key protein - claudin-1- for hepatitis C virus entry identified

For as many as 200 million people worldwide infected with hepatitis C, a leading cause of chronic liver disease, treatment options are only partially effective. But new research by Rockefeller University scientists points to a potential new target for better drugs: a key protein that resides in human liver cells that hepatitis C requires for entry.

27 Feb 2007

Cancer cells 100 times more likely to genetically mutate

When cells become cancerous, they also become 100 times more likely to genetically mutate than regular cells, researchers have found. The findings may explain why cells in a tumor have so many genetic mutations, but could also be bad news for cancer treatments that target a particular gene controlling cancer malignancy.

20 Feb 2007

Nano printing technique produces model membranes

An international team of investigators based in the United States and Germany has modified the nanoscale printing technique known as dip-pen nanolithography to create large numbers of model cell membranes.

20 Feb 2007

Genetic mutations make people susceptible to schizophrenia

Gene mutations governing a key brain enzyme make people susceptible to schizophrenia and may be targeted in future treatments for the psychiatric illness, according to MIT and Japanese researchers.

20 Feb 2007

HIV protein TAT used to pull protein Bim into cancer cells - helps kill cancer cells

Cancer cells are sick, but they keep growing because they don't react to internal signals urging them to die. Now researchers at Washington University School of Medicine in St. Louis have found an efficient way to get a messenger into cancer cells that forces them to respond to death signals. And they did it using one of the most sinister pathogens around - HIV.

15 Feb 2007

Changes in breast cancer management

Aggressive research currently underway brings hope of dramatic advances in breast cancer management, according to a new review.

12 Feb 2007

Ranbaxy and GlaxoSmithKline form alliance

Ranbaxy Laboratories announced today that the Company and GlaxoSmithKline have signed a new, multiyear R&D agreement that modifies and expands the terms of their strategic alliance established in 2003 to provide Ranbaxy expanded drug-development responsibilities and further financial opportunities.

6 Feb 2007

RNA used to turn on genes to alleviate disease

A new technique that employs RNA, a tiny chemical cousin of DNA, to turn on genes could lead to therapeutics for conditions in which nudging a gene awake would help alleviate disease, researchers at UT Southwestern Medical Center say.

28 Jan 2007

Manipulation of proliferation and differentiation of human bone marrow derived neural stem cells in vitro and in vivo

Stem cells taken from adult human bone marrow have been manipulated by scientists at the Maxine Dunitz Neurosurgical Institute at Cedars-Sinai Medical Center to generate aggregates of cells called spheres that are similar to those derived from neural stem cells of the brain.

28 Jan 2007

Artificially engineered magnetic nanoparticles for ultra-sensitive molecular imaging

Iron oxide nanoparticles have shown promise as agents for detecting tumors using magnetic resonance imaging (MRI), but such efforts have been limited by the relatively weak magnetic signal generated by these nanoparticles.

22 Jan 2007

Nanoparticles yield delivery tools for therapeutic nucleic acids

Cancer researchers hold great hope that nucleic acid-based therapeutics, such as anticancer genes, antisense oligonucleotides, and small interfering RNA (siRNA) molecules, will prove to be powerful antitumor agents.

16 Jan 2007

EDMA welcomes 7 new members

EDMA, the European Diagnostic Manufacturers Association, enlarges its membership with six new companies: BioSystems SA, Diagnostica Stago, Innogenetics, Luminex Corporation, Orion Diagnostica and Tecan, and the Foundation for Innovative New Diagnostics (FIND).

9 Jan 2007

Interleukin-13 receptor-targeted nanovesicles are a potential therapy for glioblastoma multiforme

Glioblastoma multiforme is among the most aggressive and difficult cancers to treat. Now, researchers at Penn State University have shown that a lipid-based nanoparticle, designed to bind to a specific receptor found on malignant brain cells but not healthy ones, improves the potency of a common anticancer drug and slows significantly the growth of glioblastoma in mice.

8 Jan 2007

Sigma-Aldrich grants Pfizer license to use ddRNAi

Sigma-Aldrich has announced that it has granted Pfizer a worldwide non-exclusive research license to utilize DNA-directed RNAi (ddRNAi) technology. Applications of the ddRNAi technology for research activities have been licensed exclusively by Sigma- Aldrich from Benitec Limited of Australia.

3 Jan 2007

Epidurals affect how successful breastfeeding will be

According to researchers in Australia having an epidural to relieve labour pains may affect how successful breastfeeding will be.

12 Dec 2006

Scientists discover how androgen plays a role in the development of prostate cancer

Scientists have discovered for the first time a specific biochemical pathway by which the sex hormone, androgen, increases levels of harmful chemicals called reactive oxygen species (ROS) in the prostate gland that play a role in the development of prostate cancer.

8 Nov 2006

Squalenoyl nanomedicines as potential therapeutics

Nucleoside analogs such as cytarabine and gemcitabine are powerful anticancer agents, but a simple chemical modification that causes them to assemble into stable nanoparticles could make them even more valuable in the treatment of a wide variety of cancers.

23 Oct 2006